NICE rejects Roche’s Tecentriq in new lung cancer useNICE has said in first draft guidance that Roche’s Tecentriq should not get regular NHS funding as a Share XNICE rejects Roche’s Tecentriq in new lung cancer usehttps://pharmaphorum.com/news/nice-rejects-roches-tecentriq-in-new-lung-cancer-use/
AZ’s Imfinzi approved in early lung cancer in ChinaThe Chinese regulator has approved AstraZeneca’s Imfinzi in an early form of lung cancer after treatment with chemotherapy Share XAZ’s Imfinzi approved in early lung cancer in Chinahttps://pharmaphorum.com/news/azs-imfinzi-approved-in-early-lung-cancer-in-china/
FDA grants AZ’s Imfinzi fast review in new lung cancer useThe FDA has granted AstraZeneca’s Imfinzi immunotherapy a faster six-month review in patients with extensive-stage small cell lung Share XFDA grants AZ’s Imfinzi fast review in new lung cancer usehttps://pharmaphorum.com/news/fda-grants-azs-imfinzi-fast-review-in-new-lung-cancer-use/
Merck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drugThe FDA thinks German Merck could have a breakthrough in its hands with a new lung cancer drug Share XMerck KGaA nabs FDA “Breakthrough” tag for MET-targeting lung cancer drughttps://pharmaphorum.com/news/merck-kgaa-nabs-fda-breakthrough-tag-for-met-targeting-lung-cancer-drug/
Relief for Lilly as drug from $8bn Loxo deal clears pivotal trialEli Lilly’s $8 billion acquisition of Loxo Oncology looks like it could pay off, with new data for Share XRelief for Lilly as drug from $8bn Loxo deal clears pivotal trialhttps://pharmaphorum.com/news/relief-for-lilly-as-drug-from-8bn-loxo-deal-clears-pivotal-trial/
Mixed reviews for Amgen’s KRAS drug after lung cancer data revealEagerly awaited trial data from Amgen’s latest KRAS-targeting cancer drug AMG 510 emerged over the weekend – and Share XMixed reviews for Amgen’s KRAS drug after lung cancer data revealhttps://pharmaphorum.com/news/mixed-reviews-for-amgens-kras-drug-after-lung-cancer-data-reveal/
Novartis’ lung cancer drug edges closer to market after FDA grants fast reviewAn investigational lung cancer drug from Novartis and Incyte could be on the market midway through next year Share XNovartis’ lung cancer drug edges closer to market after FDA grants fast reviewhttps://pharmaphorum.com/news/novartis-incytes-lung/
AZ gets China nod for Tagrisso in first-line lung cancerAstraZeneca has scored another approval for one of its new drugs in China, this time getting a green Share XAZ gets China nod for Tagrisso in first-line lung cancerhttps://pharmaphorum.com/news/az-gets-china-nod-for-tagrisso-in-first-line-lung-cancer/
Rova-T: the story of AbbVie’s multi-billion dollar failureRichard Staines discusses what has become one of the worst deals in pharma’s history – AbbVie’s purchase of Share XRova-T: the story of AbbVie’s multi-billion dollar failurehttps://pharmaphorum.com/r-d/views-analysis-r-d/rova-t-the-story-of-abbvies-multi-billion-dollar-failure/
